Back to Search
LIBBY SZETO, MD
MD
Obstetrics & Gynecology Physician
NPI: 1740749662IndividualAccepts Medicare
Specialties, Licenses & Credentials
Obstetrics & Gynecology PhysicianPrimary
Obstetrics & Gynecology
Code: 207V00000X
A185111(CA)
CMS Specialties
PrimaryOBSTETRICS/GYNECOLOGY
Education
UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE
Class of 2019
Research & Publications (20)
Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice.
PMID 18801896·Endocrinology·2009
7-preclinical
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
PMID 18758303·J Thorac Oncol·2008
3-trial
Enhanced cellular uptake of remnant high-density lipoprotein particles: a mechanism for high-density lipoprotein lowering in insulin resistance and hypertriglyceridemia.
PMID 18556574·Circ Res·2008
8-other
Triglyceride-rich lipoprotein-associated apolipoprotein C-III production is stimulated by plasma free fatty acids in humans.
PMID 18556566·Arterioscler Thromb Vasc Biol·2008
8-other
Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans.
PMID 18443237·Circulation·2008
4-observational
Dissociation between the insulin-sensitizing effect of rosiglitazone and its effect on hepatic and intestinal lipoprotein production.
PMID 18285418·J Clin Endocrinol Metab·2008
3-trial
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.
PMID 18172305·Cancer Res·2008
7-preclinical
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
PMID 18166842·J Thorac Oncol·2008
3-trial
A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
PMID 17255273·Clin Cancer Res·2007
3-trial
2D LnIII RuIII 2 compounds constructed from trans-[Ru(acac)2(CN)2]-. Syntheses, structures, and magnetic properties.
PMID 16903732·Inorg Chem·2006
8-other
Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer.
PMID 17409864·J Thorac Oncol·2006
3-trial
Atorvastatin induces insulin sensitization in Zucker lean and fatty rats.
PMID 15998521·Atherosclerosis·2006
4-observational
Enhancement of muscle glucose uptake by the vasopeptidase inhibitor, omapatrilat, is independent of insulin signaling and the AMP kinase pathway.
PMID 16899577·J Endocrinol·2006
7-preclinical
Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus.
PMID 15919687·Ann Oncol·2005
3-trial
Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian golden hamster.
PMID 15486228·Endocrinology·2005
7-preclinical
Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer rosiglitazone.
PMID 15504970·Diabetes·2004
7-preclinical
Intestinal lipoprotein production is stimulated by an acute elevation of plasma free fatty acids in the fasting state: studies in insulin-resistant and insulin-sensitized Syrian golden hamsters.
PMID 15271878·Endocrinology·2004
7-preclinical
A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer.
PMID 15151948·Ann Oncol·2004
3-trial
Rosiglitazone improves intestinal lipoprotein overproduction in the fat-fed Syrian Golden hamster, an animal model of nutritionally-induced insulin resistance.
PMID 15136053·Atherosclerosis·2004
4-observational
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
PMID 15020613·J Clin Oncol·2004
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 725 WELCH RD
PALO ALTO, CA 94304 - Phone
- (650) 497-8000
Quick Facts
- NPI
- 1740749662
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 7
- Publications
- 20
Are you this provider?
Claim Your Profile